Clinical efficacy of antibacterial drugs combined with Proton Pump Inhibitors and Bismuth in the treatment of Helicobacter Pylori-infected Peptic Ulcer.

Objective: To investigate the clinical efficacy of antibacterial drugs combined with proton pump inhibitors and bismuth in the treatment of Helicobacter pylori (Hp)-infected peptic ulcer. Methodology: This was a retrospective study. A total of 116 patients with Hp-infected peptic ulcer treated at Cangzhou People's Hospital from January 2023 to December 2024 were selected as study subjects and randomly divided into an observation group(n=58) treated with antibacterial drugs in addition to the treatment for the control group and a control group(n=58) received proton pump inhibitors and bismuth using the computer-based lottery method. The clinical efficacy, time to symptom subsidence treatment safety were assessed and compared between the two groups. Results: The overall response rate of the observation group was higher than that of the control group(P<0.05). Specifically, the time to symptom subsidence in the observation group was shorter than that in the control group(P<0.05), and the post-treatment levels of G-17, PGI and PGII in the observation group were lower than those in the control group(P< 0.05). Meanwhile, the post-treatment serum levels of GAS, VIP, and MOT in the observation group were higher than those in the control group(P<0.05). Additionally, the observation group reported lower post-treatment serum levels of TRX-1, TRAF1, and MMP-9 than the control group(P<0.05), with no significant differences observed in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Antibacterial drugs combined with proton pump inhibitors and bismuth are remarkably effective in treating Hp-infected peptic ulcer, which promotes the subsidence of symptoms, improves gastric function, increases gastrointestinal hormone levels.